National Pharmaceutical Council Welcomes Shire as Its Newest Member
WASHINGTON, Aug. 3, 2011 /PRNewswire-USNewswire/ -- The National Pharmaceutical Council (NPC) today welcomed global specialty biopharmaceutical company Shire plc as a new member. Dr. Jeffrey M. Jonas, senior vice president, specialty pharma R&D, will serve as Shire's representative on the NPC board of directors.
"The last few years have brought change to the health care environment that has left many important questions unresolved. For the pharmaceutical industry, how comparative effectiveness research  will be conducted and used is critical. We welcome Shire and look forward to their contribution to our shared mission of helping to answer these questions and chart the future," said NPC President Dan Leonard.
Shire, with facilities in Pennsylvania and Massachusetts, is focused on attention deficit hyperactivity disorder (ADHD), human genetic therapies (HGT) and gastrointestinal (GI) diseases as well as opportunities in other therapeutic areas to the extent they arise through acquisitions. Shire's in-licensing, merger and acquisition efforts are focused on products in specialist markets with strong intellectual property protection and global rights.
"Shire is very supportive of NPC's focus on evidence-based medicine and on policy research related to comparative effectiveness research, pharmaceutical innovation and the value of medicines," said Dr. Jonas. "We're pleased to be a part of this organization and look forward to working with NPC on issues affecting the pharmaceutical industry."
In becoming an NPC member , Shire joins with other leading research-based pharmaceutical companies, including Abbott Laboratories, Astra Zeneca LP, Bayer HealthCare Pharmaceuticals, Boehringer Ingelheim Pharmaceuticals Inc., Bristol-Myers Squibb Company, Daiichi Sankyo, Inc., Eisai inc., GlaxoSmi